Edition:
United Kingdom

Flex Pharma Inc (FLKS.OQ)

FLKS.OQ on NASDAQ Stock Exchange Global Market

1.17USD
20 Jun 2018
Change (% chg)

$-0.03 (-2.50%)
Prev Close
$1.20
Open
$1.20
Day's High
$1.20
Day's Low
$1.15
Volume
9,167
Avg. Vol
46,548
52-wk High
$8.95
52-wk Low
$1.04

Chart for

About

Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company's product candidates activate certain receptors in primary sensory neurons, which then act... (more)

Overall

Beta: --
Market Cap(Mil.): $60.74
Shares Outstanding(Mil.): 17.97
Dividend: --
Yield (%): --

Financials

  FLKS.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -2.13 -- --
ROI: -59.64 2.00 14.38
ROE: -59.69 3.49 16.08

Flex Pharma to scrap two mid-stage neuromuscular disease trials

U.S. drug developer Flex Pharma Inc said on Wednesday it plans to stop two ongoing mid-stage trials, testing its lead drug to treat neuromuscular diseases, following safety concerns.

13 Jun 2018

UPDATE 1-Flex Pharma to scrap two mid-stage neuromuscular disease trials

June 13 U.S. drug developer Flex Pharma Inc said on Wednesday it plans to stop two ongoing mid-stage trials, testing its lead drug to treat neuromuscular diseases, following safety concerns.

13 Jun 2018

Flex Pharma to cut 60 percent of workforce

June 13 U.S. drug developer Flex Pharma Inc said on Wednesday it plans to reduce its workforce by 60 percent, as part of a restructuring, and was ending certain ongoing mid-stage trials.

13 Jun 2018

BRIEF-Flex Pharma Reports Q1 Loss Per Share $0.46

* Q1 EARNINGS PER SHARE VIEW $-0.49 -- THOMSON REUTERS I/B/E/S

02 May 2018

BRIEF-Flex Pharma Reports Positive Topline Data From Exploratory Phase 2 Trial Of FLX-787 In Multiple Sclerosis

* FLEX PHARMA REPORTS POSITIVE TOPLINE DATA FROM EXPLORATORY PHASE 2 TRIAL OF FLX-787 IN MULTIPLE SCLEROSIS

26 Mar 2018

BRIEF-Flex Pharma Reports Q4 Loss Per Share $0.46

* EXPECTS TO HAVE SUFFICIENT CAPITAL TO FUND ITS OPERATIONS TO MID 2019 Source text for Eikon: Further company coverage:

07 Mar 2018

BRIEF-Flex Pharma Engaged Investment Banking Firm To Assist With Consideration Of Strategic Alternatives For Co's Hotshot Consumer Product Business‍​

* FLEX PHARMA - ENGAGED INVESTMENT BANKING FIRM TO ASSIST WITH CONSIDERATION OF STRATEGIC ALTERNATIVES FOR CO'S HOTSHOT CONSUMER PRODUCT BUSINESS‍​ Source text: (http://bit.ly/2F0i8Tu) Further company coverage:

22 Jan 2018

Earnings vs. Estimates